Closing the Gaps in Stroke Care: Access, Innovation and Global Equity

Key Takeaways

• 12 million strokes occur worldwide each year
• One‑quarter of survivors die within a year
• Medtronic partners with governments, Philips, global coalitions
• Time‑critical: 1.9 million neurons lost per minute
• New liquid embolic device approved for chronic subdural hematoma

Summary

Linnea Burman, President of Medtronic Neurovascular, highlighted that nearly 12 million people suffer a stroke each year and one in four die within a year, underscoring persistent global gaps in prevention, access, and long‑term care. She emphasized that rapid treatment is vital—about 1.9 million neurons are lost each minute during an acute ischemic event. Medtronic is leveraging partnerships with governments, industry peers like Philips, and global coalitions to expand equitable stroke care and generate local evidence. The company also introduced a liquid embolic device for chronic subdural hematoma, reflecting a patient‑first innovation agenda.

Pulse Analysis

The global stroke burden remains staggering, with roughly 12 million incidents annually and a 25% one‑year mortality rate. Rapid intervention is critical; neuroscientists estimate that 1.9 million neurons die each minute during an acute ischemic stroke, a loss that translates into permanent disability and heightened health‑care expenditures. This urgency drives clinicians and policymakers to prioritize faster diagnosis, streamlined emergency pathways, and public education on symptom recognition, especially in low‑ and middle‑income regions where resources are scarce.

Medtronic’s strategy hinges on collaborative ecosystems that unite industry, governments, and global health entities. Partnerships with firms such as Philips, involvement in the Global Stroke Action Coalition, and initiatives like Mission Thrombectomy enable the company to dismantle structural barriers, generate country‑specific clinical evidence, and demonstrate the economic case for advanced therapies. By educating policymakers and clinicians, these alliances aim to standardize stroke protocols, expand training, and ultimately equalize access across disparate health systems.

At the heart of Medtronic’s approach is a patient‑centric innovation model. Direct engagement with stroke survivors informs product design, ensuring technologies address real‑world needs rather than theoretical gaps. The recent U.S. approval of a liquid embolic device for chronic subdural hematoma exemplifies this focus, offering a minimally invasive option that can improve outcomes for a condition often overlooked in stroke care. Continued investment in R&D, coupled with a robust clinical leadership team, positions Medtronic to deliver next‑generation neurovascular solutions that could reshape treatment paradigms and reduce the global stroke toll.